Form 4: Rapport Therapeutics COO Granted Stock Options
SEC Form 4 Filing
Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, was granted stock options for 129,000 shares on February 3, 2025.
Summary
- Cheryl Gault, the Chief Operating Officer of Rapport Therapeutics, was granted stock options on February 3, 2025.
- The options are for 129,000 shares of Rapport Therapeutics common stock.
- The exercise price of the options is $16.60 per share.
- The options vest in 48 equal monthly installments starting January 1, 2025, contingent upon continued service.
- The options expire on February 3, 2035.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and indicates confidence in the executive's future contributions. However, it's not a major event that would drastically alter the company's outlook.
Positives
- The grant of stock options to the COO aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued service and commitment to the company's long-term success.
Future Outlook
The vesting schedule suggests an expectation of continued service from the COO over the next four years.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Biogen, and Gilead Sciences routinely use stock options to incentivize their executives.
- The size of the grant (129,000 shares) would need to be compared to grants made to executives in comparable roles at similar-sized biotech companies to assess its relative value.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
- Employees may see this as a positive signal about the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Start date for monthly vesting of stock options. |
| February 3, 2025 | Date of stock option grant. |
| February 3, 2035 | Expiration date of stock options. |
| February 4, 2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.